Pharvaris (NASDAQ:PHVS) CFO Sells $303,100.00 in Stock

Pharvaris N.V. (NASDAQ:PHVS) CFO David Nassif sold 10,000 shares of Pharvaris stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $30.31, for a total value of $303,100.00. Following the completion of the sale, the chief financial officer owned 120,300 shares in the company, valued at approximately $3,646,293. This represents a 7.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Pharvaris Stock Performance

Shares of Pharvaris stock traded up $0.20 during midday trading on Tuesday, reaching $29.88. 191,721 shares of the company’s stock traded hands, compared to its average volume of 227,155. The stock has a 50 day moving average of $28.52 and a 200-day moving average of $26.90. Pharvaris N.V. has a 12 month low of $15.46 and a 12 month high of $33.33. The company has a market cap of $1.95 billion, a PE ratio of -9.40 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.12. On average, equities analysts anticipate that Pharvaris N.V. will post -3.25 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research note on Tuesday, April 21st. HC Wainwright reissued a “buy” rating and issued a $60.00 target price on shares of Pharvaris in a report on Tuesday, March 3rd. Citizens Jmp cut their target price on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating on the stock in a research note on Wednesday, May 13th. Wolfe Research assumed coverage on Pharvaris in a report on Thursday, April 9th. They set an “outperform” rating and a $42.00 price target for the company. Finally, Wall Street Zen raised Pharvaris from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Pharvaris has a consensus rating of “Moderate Buy” and an average target price of $49.18.

Hedge Funds Weigh In On Pharvaris

A number of hedge funds have recently added to or reduced their stakes in PHVS. Tudor Investment Corp ET AL bought a new position in shares of Pharvaris during the third quarter valued at $1,943,000. Patient Square Capital LP increased its holdings in Pharvaris by 41.4% in the 3rd quarter. Patient Square Capital LP now owns 345,381 shares of the company’s stock worth $8,617,000 after buying an additional 101,098 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Pharvaris by 710.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 27,085 shares of the company’s stock worth $676,000 after buying an additional 23,743 shares in the last quarter. Integral Health Asset Management LLC purchased a new position in Pharvaris in the 3rd quarter worth about $4,990,000. Finally, Boothbay Fund Management LLC raised its position in Pharvaris by 735.1% in the 3rd quarter. Boothbay Fund Management LLC now owns 135,181 shares of the company’s stock worth $3,373,000 after buying an additional 118,994 shares during the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.